|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||179.42 - 181.87|
|52-week range||179.42 - 181.87|
|Beta (5Y monthly)||0.84|
|PE ratio (TTM)||N/A|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Does the June share price for Seagen Inc. ( NASDAQ:SGEN ) reflect what it's really worth? Today, we will estimate the...
BOTHELL, Wash. & COPENHAGEN, Denmark, June 06, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabilit